Here are the DEF 14A proxy statements from Teva Pharm Indus Ltd (TEVJF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
Teva Pharmaceutical Industries Ltd. is asking shareholders to reappoint Dr. Sol J. Barer as director through 2029, approve executive pay on an advisory basis, and ratify Kesselman & Kesselman (PwC network) as auditor through the 2027 meeting. The Board highlights progress on its “Pivot to Growth” strategy, emphasizing double‑digit growth for key innovative drugs AUSTEDO, UZEDY (including an FDA indication expansion for Bipolar I disorder) and AJOVY, as well as advancement of late‑stage assets like olanzapine LAI and duvakitug, which generated a $500 million Phase 3 milestone payment recorded as 2025 revenue. Teva reports 2025 global revenue growth in local currency, continued net debt reduction, and a stronger balance sheet supported by sustainable finance, including about $7.5 billion of sustainability‑linked bonds and a $1.8 billion sustainability‑linked revolving credit facility. The proxy details Board composition, committee structure, AI and cybersecurity oversight, human capital initiatives for Teva’s 33,950 employees, and an executive compensation framework heavily weighted to variable, performance‑based pay, alongside strengthened stock‑ownership guidelines and no hedging or repricing of underwater options.